Dopamine Agonist Therapy in Advanced Parkinson’s Disease

Dopamine Agonist Therapy in Advanced Parkinson’s Disease

Bibliographic Details
Main Author:	Heinz Reichmann
Format:	Article
Language:	English
Published:	Korean Movement Disorder Society 2009-05-01
Series:	Journal of Movement Disorders
Online Access:	http://e-jmd.org/upload/jmd-2-1-10-3.pdf

Similar Items

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01)

The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01)

Dopamine agonists and risk: Impulse control disorders in Parkinson's; Disease
by: Voon, V, et al.
Published: (2011)

Dopamine agonists and risk: impulse control disorders in Parkinson's disease.
by: Voon, V, et al.
Published: (2011)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01)

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole
by: M. R. Nodel
Published: (2011-12-01)

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
by: Hiu Fung Wu, et al.
Published: (2024-01-01)

Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s
by: McIntosh, E, et al.
Published: (2021)

Dopamine D<sub>1</sub> Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
by: Mechelle M. Lewis, et al.
Published: (2023-05-01)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
by: Stuart H. Isaacson, et al.
Published: (2023-01-01)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
by: Grossman, A, et al.
Published: (1985)

Dopaminergic agonists in Parkinson's disease
by: A. Alonso Cánovas, et al.
Published: (2014-05-01)

Role of dopamine in the pathophysiology of Parkinson’s disease
by: Zhi Dong Zhou, et al.
Published: (2023-09-01)

Dopamine dysregulation syndrome in Parkinson’s disease
by: A V Nikitina, et al.
Published: (2013-03-01)

The use of the dopamine agonist cabergoline in the therapy of surgically induced endometriosis in rats
by: M.I. Yarmolinskaya, et al.
Published: (2018-12-01)

The outcome of macroprolactinomas resistant to dopamine agonists
by: Coculescu, M, et al.
Published: (2005)

Impulse control disorders and dopamine agonists
by: D. Martins, et al.
Published: (2021-04-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease
by: Satoshi Goto, et al.
Published: (2023-04-01)

α-Synuclein and dopamine at the crossroads of Parkinson's disease.
by: Venda, L, et al.
Published: (2010)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
by: Sinn, D, et al.
Published: (1985)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
by: M.L. Costa, et al.
Published: (2022-06-01)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
by: Vladimir M. Pogorelov, et al.
Published: (2023-11-01)

Effects of dopamine on reinforcement learning and consolidation in Parkinson’s disease
by: John P Grogan, et al.
Published: (2017-07-01)

Effects of dopamine on reinforcement learning and consolidation in Parkinson’s disease
by: Grogan, J, et al.
Published: (2017)

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis
by: Xiang-Ting Chen, et al.
Published: (2023-06-01)

Dopamine Therapy and the Regulation of Oxidative Stress and Mitochondrial DNA Copy Number in Patients with Parkinson’s Disease
by: Shih-Hsuan Chen, et al.
Published: (2020-11-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)

Relationship of irisin with disease severity and dopamine uptake in Parkinson's disease patients
by: Xiaoxue Shi, et al.
Published: (2024-01-01)

DECISION MAKING IN PARKINSON’S DISEASE: A PRELIMINARY STUDY INVESTIGATING THE INFLUENCE OF DOPAMINE REPLACEMENT THERAPY ON DECISIONAL PROCESSES IN PATIENTS AFFECTED BY PARKINSON’S DISEASE
by: Laura Colautti, et al.
Published: (2023-10-01)

Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder
by: Drew, DS, et al.
Published: (2020)

Dopamine enhances willingness to exert effort for reward in Parkinson's disease.
by: Chong, T, et al.
Published: (2015)

Macroautophagy, alpha-synuclein and dopamine neurotransmission: implications for Parkinson’s disease
by: Hunn, BHM
Published: (2017)

Dopamine Neuron Challenge Test for early detection of Parkinson’s disease
by: Jingheng Zhou, et al.
Published: (2021-12-01)

Dopamine Does Not Appear to Affect Mental Rotation in Parkinson’s Disease
by: Gregory P. Crucian, et al.
Published: (2014-10-01)

Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
by: Lijuan Hou, et al.
Published: (2017-11-01)

Dopamine Genetics: Substance Use Disorders vs. Parkinson’s Disease
by: Z. Carl Lin, et al.
Published: (2019-12-01)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
by: Sunita M C De Sousa
Published: (2023-01-01)

Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy
by: Ilya Sukhanov, et al.
Published: (2022-12-01)